You are here

  • Home
  • Archive
  • Volume 15, Issue 2
  • Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)

Article info

Article menu

Download PDFPDF

Addiction
Protocol
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)

Authors

  • Kathryn Fletcher The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Nadine Ezard The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, AustraliaAlcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Krista J Siefried The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, AustraliaAlcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Harriet MacDonald The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Liam Acheson The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, AustraliaAlcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Gillinder Bedi Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, AustraliaSubstance Use Research Group, Orygen Ltd, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Alexandre Guerin Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, AustraliaSubstance Use Research Group, Orygen Ltd, Parkville, Victoria, Australia PubMed articlesGoogle scholar articles
  • Elizabeth Knock Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Michael Millard Clinical Research Unit for Anxiety and Depression, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Robert May Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Jonathan Brett St Vincent's Clinical School; School of Population Health, University of New South Wales, Sydney, New South Wales, AustraliaClinical Pharmacology and Therapeutics, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Jess Doumany Australian Injecting and Illicit Drug Users League, Canberra, Canberra, Australia PubMed articlesGoogle scholar articles
  • Celia Morgan Department of Psychology, University of Exeter, Exeter, Devon, UKImperial College London, London, UK PubMed articlesGoogle scholar articles
  • Brendan Clifford The National Centre for Clinical Research on Emerging Drugs; The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, AustraliaAlcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Kathryn Fletcher; k.fletcher{at}unsw.edu.au
View Full Text

Citation

Fletcher K, Ezard N, Siefried KJ, et al
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)
BMJ Open 2025;15:e092504. doi: 10.1136/bmjopen-2024-092504

Publication history

  • Received August 16, 2024
  • Accepted January 9, 2025
  • First published February 10, 2025.
Online issue publication 
February 10, 2025
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.